In Clinical pharmacology and therapeutics ; h5-index 0.0
Lower clearance of immune checkpoint inhibitors is a predictor of improved overall survival (OS) in patients with advanced cancer. We investigated a novel approach using machine learning to identify a baseline composite cytokine signature via clearance, which, in turn, could be associated with OS in advanced melanoma. Peripheral nivolumab clearance and cytokine data from patients treated with nivolumab in two phase III studies (n = 468 [pooled]) and another phase III study (n = 158) were used for machine-learning model development and validation, respectively. Random forest (Boruta) algorithm was used for feature selection and classification of nivolumab clearance. The 16 top-ranking baseline inflammatory cytokines reflecting immune-cell modulation were selected as a composite signature to predict nivolumab clearance (AUC = 0.75; accuracy = 0.7). Predicted clearance (high vs. low) via the cytokine signature was significantly associated with OS across all three studies (P < 0.01), regardless of treatment (nivolumab vs. chemotherapy).
Wang Rui, Shao Xiao, Zheng Junying, Saci Abdel, Qian Xiaozhong, Pak Irene, Roy Amit, Bello Akintunde, Rizzo Jasmine I, Hosein Fareeda, Moss Rebecca A, Wind-Rotolo Megan, Feng Yan
biomarkers, oncology, precision medicine, survival analysis, translational pharmacokinetics/pharmacodynamics